XML 29 R20.htm IDEA: XBRL DOCUMENT
v3.24.3

Company information - Significant events in the first half of 2024 (Details) € / shares in Units, $ in Millions |  |  |  |  |  | 6 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Mar. 18, 2024 | Jan. 18, 2024 EUR (€) shares | Jan. 04, 2024 EUR (€) € / shares shares | Jan. 03, 2024 € / shares | Dec. 08, 2022 | Jun. 30, 2024 EUR (€) shares | Mar. 07, 2024 site | Jan. 18, 2024 USD ($) | Dec. 31, 2023 shares | Nov. 28, 2022 shares | May 16, 2022 EUR (€)
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |
Notional Amount | $ |  |  |  |  |  |  |  | $ 25 |  |  |
Subscription of borrowings and warrants net of transaction cost |  |  |  |  |  | € 24,911,000 |  |  |  |  |
Finance contract with EIB |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |
Percentage of share capital held by counterparty if all outstanding warrants are exercised |  |  |  |  |  | 9.90% |  |  |  |  |
Notional Amount |  |  |  |  |  |  |  |  |  |  | € 50,000,000
Subscription of borrowings and warrants net of transaction cost |  | € 25,000,000 |  |  |  |  |  |  |  |  |
Finance contract with EIB, first tranche (Tranche A) |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |
Subscription of borrowings and warrants net of transaction cost |  |  |  |  |  | € 25,000,000.0 |  |  |  |  |
Number of shares per instrument | shares |  |  |  |  |  | 1.27 |  |  | 1.20 | 1.00 |
Interest rate |  |  |  |  | 8.00% |  |  |  |  |  |
Maturity term after the disbursement of the tranche |  |  |  |  | 4 years |  |  |  |  |  |
Aggregate amount to be received under the conditions precedent to the EIB Financing |  | € 18,000,000 |  |  |  |  |  |  |  |  |
Finance contract with EIB, first tranche (Tranche A) | Financial liabilities at amortized cost |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |
Notional Amount |  |  |  |  |  | € 25,000,000 |  |  |  |  |
Finance contract with EIB, second tranche (Tranche B) |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |
Number of warrants issued | shares |  | 3,144,654 | 3,144,654 |  |  |  |  |  |  |  |
Percentage of company's share capital outstanding, issued as warrants |  |  | 6.07% |  |  |  |  |  |  |  |
Exercise price of warrant | € / shares |  |  | € 3.95 | € 3.95 |  |  |  |  |  |  |
Exercise price of warrants as a percentage of volume-weighted average price of the Company's shares |  |  |  | 95.00% |  |  |  |  |  |  |
Term of warrants |  |  | 12 years |  |  |  |  |  |  |  |
Shares issuable upon exercise of warrants | shares |  |  | 3,144,654 |  |  |  |  |  |  |  |
Maximum gross proceeds |  |  | € 12,421,383 |  |  |  |  |  |  |  |
Subscription of borrowings and warrants net of transaction cost |  |  | € 25,000,000.0 |  |  |  |  |  |  |  |
Number of shares per instrument | shares |  |  | 1.00 |  |  | 1.00 |  |  |  |  |
Interest rate |  | 7.00% |  |  |  |  |  | 7.00% |  |  |
Maturity term after the disbursement of the tranche |  | 3 years |  |  |  |  |  |  |  |  |
Aggregate amount to be received under the conditions precedent to the EIB Financing |  | € 70,000,000 |  |  |  |  |  |  |  |  |
Minimum upfront payments for out-licensing, partnership or royalty transaction |  | 10,000,000 |  |  |  |  |  |  |  |  |
Finance contract with EIB, second tranche (Tranche B) | Financial liabilities at amortized cost |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |
Notional Amount |  | € 25,000,000 |  |  |  |  |  |  |  |  |
Warrant agreement with the European Investment Bank |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |
Maturity term of warrants |  |  | 12 years |  |  |  |  |  |  |  |
NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |
Number of sites operating under central IRB overseeing | site |  |  |  |  |  |  | 152 |  |  |  |
Percentage of patients randomized in the main cohort |  |  |  |  |  |  | 60.00% |  |  |  |
LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |
Treatment period under study | 168 days |  |  |  |  |  |  |  |  |  |
Drawdown of borrowings | Finance contract with EIB, second tranche (Tranche B) |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |  |  |  |
Interest rate |  | 7.00% |  |  |  |  |  | 7.00% |  |  |
Maturity term after the disbursement of the tranche |  | 3 years |  |  |  |  |  |  |  |  |

X
- Definition The interest rate on borrowings. [Refer: Borrowings] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 7 -IssueDate 2023-01-01 -Paragraph 7 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_BorrowingsInterestRate
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The nominal or face amount of a financial instrument, used to calculate payments made on that instrument. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_NotionalAmount
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from borrowings obtained. [Refer: Borrowings] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2023-01-01 -Paragraph 17 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate amount to be received by the company, either in exchange for new shares of the Company or through the receipt of upfront or milestone payments, pursuant to the debt arrangement. + References No definition available. + Details
Name: | iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments
Namespace Prefix: | iva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Exercise price of warrants issued, represented as a percentage of volume-weighted average price of the Company's shares. + References No definition available. + Details
Name: | iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maturity term of the warrants issued by the entity. + References No definition available. + Details
Name: | iva_ClassOfWarrantOrRightMaturityTerm
Namespace Prefix: | iva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References No definition available. + Details
Name: | iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
Namespace Prefix: | iva_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + References No definition available. + Details
Name: | iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix: | iva_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References No definition available. + Details
Name: | iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems
Namespace Prefix: | iva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | iva_IfrsDebtInstrumentTerm
Namespace Prefix: | iva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum gross proceeds from receivable upon exercise of warrants. + References No definition available. + Details
Name: | iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants
Namespace Prefix: | iva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of minimum upfront payments for out-licensing, partnership or royalty transaction. + References No definition available. + Details
Name: | iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction
Namespace Prefix: | iva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of sites operating under central IRB overseeing + References No definition available. + Details
Name: | iva_NumberOfSitesOperatingUnderCentralIrbOverseeing
Namespace Prefix: | iva_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of warrants issued + References No definition available. + Details
Name: | iva_NumberOfWarrantsIssued
Namespace Prefix: | iva_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of Company's share capital outstanding, issued as warrants by the entity. + References No definition available. + Details
Name: | iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of patients randomized in the main cohort + References No definition available. + Details
Name: | iva_PercentageOfPatientsRandomizedInMainCohort
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of share capital held by counterparty if all outstanding warrants are exercised + References No definition available. + Details
Name: | iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised
Namespace Prefix: | iva_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Shares issuable upon exercise of warrants. + References No definition available. + Details
Name: | iva_SharesIssuableUponExerciseOfWarrants
Namespace Prefix: | iva_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Treatment period under study + References No definition available. + Details
Name: | iva_TreatmentPeriodUnderStudy
Namespace Prefix: | iva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of warrants. + References No definition available. + Details
Name: | iva_WarrantsTerm
Namespace Prefix: | iva_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_DrawdownOfBorrowingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |